ClinicalTrials.Veeva

Menu

Caffeine Disposition After Inhalation

University of Tennessee logo

University of Tennessee

Status

Completed

Conditions

Healthy

Treatments

Dietary Supplement: Caffeine

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT02184104
13-02648-FB
1R03DA035347-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to determine how fast caffeine gets into your body with a product called Aeroshot™. Aeroshot™ is a lipstick sized device that you slide open and then put your mouth over the opening and inhale. A fine powder containing 100 mg of caffeine is deposited on your tongue and the inside of your mouth. Caffeine will be absorbed through the membranes in your mouth or swallowed and then absorbed in your stomach. We will compare the absorption of caffeine after using the Aeroshot™ with the absorption after drinking an energy drink by taking 15 blood samples over 8 hours and measuring the caffeine levels in your blood. You will also be asked to fill out some scales to measure the effects you feel after the caffeine dose. We hypothesize that caffeine absorption after inhalation will be faster than after an energy drink.

Enrollment

24 patients

Sex

All

Ages

21 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • healthy volunteer
  • non-smoker

Exclusion criteria

  • Take chronic medication
  • Co-existing diseases
  • Platelet count less than 100,000/uL (per microliter)
  • Acute or chronic psychiatric condition
  • Consume more than 300 mg of caffeine per day
  • Participated in another study within last 30 days or donated blood in last 6 weeks

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

24 participants in 2 patient groups

Aeroshot
Active Comparator group
Description:
A single 100 mg caffeine dose administered using the Aeroshot device.
Treatment:
Dietary Supplement: Caffeine
Energy Drink
Active Comparator group
Description:
A single 100 mg caffeine dose administered as an oral solution.
Treatment:
Dietary Supplement: Caffeine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems